The expression level of TIMP metallopeptidase inhibitor 1 (TIMP1), which plays a key role in liver fibrosis associated with extracellular matrix composition, was significantly reduced in the ALS-L1023 high-dose group compared to the CDHF group, with a dose-dependent decreasing pattern observed (Figure 3A, p = 0.0306). Here, TIMP1 is linked to Hepatic fibrosis.